Philip Jones

7.8k citations

92 papers · 3.6k indexed · h-index 33

Molecular Biology top 2%
- Receptor Mechanisms and Signaling 22
- Histone Deacetylase Inhibitors Research 19
- Protein Degradation and Inhibitors 19
- Protein Kinase Regulation and GTPase Signaling 11
- DNA Repair Mechanisms 9
Oncology top 2%
- Peptidase Inhibition and Analysis 12
- PARP inhibition in cancer therapy 10
Cellular and Molecular Neuroscience top 5%
- Neurotransmitter Receptor Influence on Behavior 8
Organic Chemistry top 5%
Pharmacology top 5%

Co-authors: Christian Steinkühler Michael Rowley Raffaele De Francesco Paola Gallinari Andrea Carfı́Carlo Toniatti Petra Neddermann Rita Scarpelli
Cited by: Molecular Biology Oncology Cellular and Molecular Neuroscience
Journals: Nature (1 paper)Proceedings of the National Academy of Sciences (1 paper)Journal of Biological Chemistry (2 papers)
Partner nations: United States Italy United Kingdom

In The Last Decade

Philip Jones

91 papers receiving 3.5k citations

Peers

Countries citing papers authored by Philip Jones

Since Specialization

Citations

This map shows the geographic impact of Philip Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Jones more than expected).

Fields of papers citing papers by Philip Jones

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Jones. The network helps show where Philip Jones may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Philip Jones, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Philip Jones Line = papers co-authored together Philip Jones links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	CREB-binding protein/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in triple-negative breast cancer JCI Insight ·Xueying Yuan,Xiaoxin Hao,Hilda L. Chan,Na Zhao,Diego A. Pedroza,Fengshuo Liu,Kang Le,Alex J. Smith,Sebastian J. Calderon,Nadia Lieu,Michael Soth,Philip Jones,Xiang H.-F. Zhang,Jeffrey M. Rosen	2024	3
2	TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding Molecular Metabolism ·Nina Dedic,Lien Wang,Éva Hajós‐Korcsok,Jacob Hecksher‐Sørensen,Urmas Roostalu,Steven P. Vickers,Serena Wu,Christoph Anacker,Colleen Synan,Philip Jones,Snežana Milanović,Seth C. Hopkins,Linda J. Bristow,Kenneth S. Koblan	2024	11
3	Identification of Nonfunctional Alternatively Spliced Isoforms of STING in Human Acute Myeloid Leukemia Cancer Research Communications ·Akash R. Boda,Arthur Liu,Susana Castro-Pando,Benjamin T. Whitfield,Jeffrey J. Molldrem,Gheath Alatrash,Maria Emilia Di Francesco,Philip Jones,Casey R. Ager,Michael A. Curran	2024	1
4	TAAR1 Agonist Ulotaront Improves Glycemic Control and Reduces Body Weight in Rodent Models of Diabetes, Obesity, and Iatrogenic Weight Gain CNS Spectrums ·Nina Dedic,Philip Jones,Éva Hajós‐Korcsok,Colleen Synan,Serena Wu,Christoph Anacker,S P Vickers,Jacob Hecksher‐Sørensen,Courtney Zeni,Snežana Milanović,Seth C. Hopkins,Linda J. Bristow,Kenneth S. Koblan	2023	1
5	Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6 Cancer Research ·Alexey V. Sorokin,Preeti Kanikarla Marie,Lea Bitner,Muddassir Syed,Melanie Woods,Ganiraju C. Manyam,Lawrence N. Kwong,Benny Johnson,Van K. Morris,Philip Jones,David G. Menter,Michael S. Lee,Scott Kopetz	2022	37
6	Morphological screening of mesenchymal mammary tumor organoids to identify drugs that reverse epithelial-mesenchymal transition Nature Communications ·Na Zhao,Reid T. Powell,Xueying Yuan,Goeun Bae,Kevin Roarty,Fabio Stossi,Martina Strempfl,Michael J. Toneff,Hannah L. Johnson,Sendurai A. Mani,Philip Jones,Clifford Stephan,Jeffrey M. Rosen	2021	43
7	Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP–ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells Bioorganic & Medicinal Chemistry Letters ·Federica Ferrigno,Danila Branca,Olaf Kinzel,Samuele Lillini,Laura Llauger Bufi,Edith Monteagudo,Ester Muraglia,Michael Rowley,Carsten Schultz‐Fademrecht,Carlo Toniatti,Caterina Torrisi,Philip Jones	2009	14
8	Identification and SAR of novel pyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1) Bioorganic & Medicinal Chemistry Letters ·Giovanna Pescatore,Danila Branca,Fabrizio Fiore,Olaf Kinzel,Laura Llauger Bufi,Ester Muraglia,Federica Orvieto,Michael Rowley,Carlo Toniatti,Caterina Torrisi,Philip Jones	2009	17
9	A Fluorescence-Based Assay for Monoacylglycerol Lipase Compatible with Inhibitor Screening Assay and Drug Development Technologies ·Yuren Wang,Pranab K. Chanda,Philip Jones,Jeffrey D. Kennedy	2008	23
10	Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors Bioorganic & Medicinal Chemistry Letters ·Rita Scarpelli,Annalise Di Marco,Federica Ferrigno,Ralph Laufer,Isabella Marcucci,Ester Muraglia,Jesus M. Ontoria,Michael Rowley,Sergio Serafini,Christian Steinkühler,Philip Jones	2008	17
11	Identification of Critical Amino Acid Residues for Human iNOS Functional Activity The Protein Journal ·Saule Naureckiene,Sreekumar Kodangattil,Edward Kaftan,Philip Jones,Jeffrey D. Kennedy,Kathryn E. Rogers,Pranab K. Chanda	2008	6
12	Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure Cardiovascular Research ·Pasquale Gallo,Michael V.G. Latronico,Paolo Gallo,Séréna Grimaldi,Francesco Borgia,Matilde Todaro,Philip Jones,Paola Gallinari,Raffaele De Francesco,Gennaro Ciliberto,Christian Steinkühler,Giovanni Esposito,Gianluigi Condorelli	2008	135
13	Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases Proceedings of the National Academy of Sciences ·Armin Lahm,Chantal Paolini,Michele Pallaoro,Maria Chiara Nardi,Philip Jones,Petra Neddermann,Sonia Sambucini,Matthew J. Bottomley,Paola Lo Surdo,Andrea Carfı́,Ute Koch,Raffaele De Francesco,Christian Steinkühler,Paola Gallinari	2007	443
14	Species‐specificin vitropharmacological effects of the cannabinoid receptor 2 (CB₂) selective ligand AM1241 and its resolved enantiomers British Journal of Pharmacology ·Brendan Bingham,Philip Jones,A J Uveges,S Kotnis,P Lu,V A Smith,S‐C Sun,Lauren Β. Resnick,M Chlenov,Y He,B W Strassle,T A Cummons,M J Piesla,J E Harrison,Garth T. Whiteside,J D Kennedy	2007	78
15	A novel scintillation proximity assay for fatty acid amide hydrolase compatible with inhibitor screening Analytical Biochemistry ·Yuren Wang,Jun Xu,Albert J. Uveges,Manjunath Ramarao,Kathryn E. Rogers,Philip Jones	2006	6
16	High-Throughput Screening for the Discovery of Inhibitors of Fatty Acid Amide Hydrolase Using a Microsome-Based Fluorescent Assay SLAS DISCOVERY ·Yuren Wang,Fernando Ramirez,Girija Krishnamurthy,A. Gilbert,Nina Kadakia,Jun Xu,Gary Kalgaonkar,Manjunath Ramarao,Wade Edris,Kathryn E. Rogers,Philip Jones	2006	9
17	A series of novel, potent, and selective histone deacetylase inhibitors Bioorganic & Medicinal Chemistry Letters ·Philip Jones,Sergio Altamura,Prasun K. Chakravarty,Ottavia Cecchetti,Raffaele De Francesco,Paola Gallinari,Raffaele Ingenito,Peter T. Meinke,Alessia Petrocchi,Michael Rowley,Rita Scarpelli,Sergio Serafini,Christian Steinkühler	2006	52
18	RGS7 complex formation and colocalization with the G?5 subunit in the adult rat brain and influence on G?5?2-mediated PLC? signaling Journal of Neuroscience Research ·Jinjun Liang,Hui Chen,Philip Jones,Xavier Khawaja	2000	26
19	Probing the Potassium Channel K_vβ1/K_v1.1 Interaction Using a Random Peptide Display Library Annals of the New York Academy of Sciences ·STEPHEN J. LOMBARDI,Amy Truong,Paul Spence,Kenneth J. Rhodes,Philip Jones	1999	2
20	Cloning and tissue distribution of the human G protein β5 cDNA Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·Philip Jones,Stephen J. Lombardi,Mark I. Cockett	1998	29

About Philip Jones

Philip Jones is a scholar working on Cellular and Molecular Neuroscience, Oncology and Molecular Biology, having authored 92 papers that have together received 3.6k indexed citations. Recurring topics across this work include Receptor Mechanisms and Signaling (22 papers), Histone Deacetylase Inhibitors Research (19 papers), Protein Degradation and Inhibitors (19 papers), Peptidase Inhibition and Analysis (12 papers), Protein Kinase Regulation and GTPase Signaling (11 papers), PARP inhibition in cancer therapy (10 papers), DNA Repair Mechanisms (9 papers) and Neurotransmitter Receptor Influence on Behavior (8 papers). The work is most often cited by research in Molecular Biology (2.7k citations), Oncology (1.0k citations) and Cellular and Molecular Neuroscience (585 citations). Philip Jones has collaborated with scholars based in United States, Italy and United Kingdom. Frequent co-authors include Christian Steinkühler, Michael Rowley, Raffaele De Francesco, Paola Gallinari, Andrea Carfı́, Carlo Toniatti, Petra Neddermann, Rita Scarpelli, Paola Lo Surdo and Matthew J. Bottomley. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact